Molecular Weight(MW): 300.05
Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. DMF is recommended for dissolution.
Cited by 97 Publications
Purity & Quality Control
Choose Selective DNA/RNA Synthesis Inhibitors
|Description||Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. DMF is recommended for dissolution.|
|Features||One of the most widely used and most potent chemotherapeutic agents.|
Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, which culminates in the activation of apoptosis.  Cisplatin (30 μM) treated for 6 h induces an apparent activation of Erk in HeLa cells, which is sustained over the following 14 h period. Cisplatin also shows an effective antineoplastic activity by inducing tumor cells death. Cisplatin displays ability to cause renal proximal tubular cell (RPTC) apoptosis, causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively.  Cisplatin (800 μM) causes typical features of necrosis of RPTC after treatment for 4 hr. 
|In vivo||Cisplatin has been demonstrated to be efficient in regression tumor growth in a wide variety of animal tumors models, including head and neck cancer xenografts, cervical squamous carcinoma xenografts, testicular carcinoma xenografts, ovarian cancer xenografts, breast carcinoma xenografts, colonic carcinoma, heterotransplanted hepatoblastoma, and so on. Cisplatin (5 mg/kg) given weekly i.v. at the day 1 and 7 induces a tumor growth inhibition (GI) of 77.5% and 85.1% of the serous xenografts Ov.Ri(C) and OVCAR-3, respectively. |
-  Siddik ZH. Oncogene, 2003, 22(47), 7265-7279.
-  Wang X, et al. J Biol Chem, 2000, 275(50), 39435-39443.
-  Sorenson CM, et al. Cancer Res, 1988, 48(16), 4484-4488.
|temperature in solvent (should be freshly prepared each time)|
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04000906||Not yet recruiting||Drug: NAB paclitaxel|Drug: Cisplatin||Peritoneal Carcinomatosis||University Hospital Geneva||September 2019||Phase 1|
|NCT03817970||Recruiting||Drug: Granisetron|Drug: Ondansetron|Drug: Palonosetron||Nephrotoxicity||University of Colorado Denver|Memorial Sloan Kettering Cancer Center|Rutgers University|National Institute of General Medical Sciences (NIGMS)||June 26 2019||Not Applicable|
|NCT03918382||Recruiting||Other: Electronic Patient-Reported Outcome||Head and Neck Cancer|Radiotherapy Side Effect||Rigshospitalet Denmark|Danish Comprehensive Cancer Center|Danish Cancer Society|University of Copenhagen|Danish Head and Neck Cancer Group|Herlev Hospital|Zealand University Hospital|Odense University Hospital|Aalborg University Hospital|Aarhus University Hospital||June 13 2019||Not Applicable|
|NCT03644589||Withdrawn||Biological: Pembrolizumab|Drug: Cisplatin||Estrogen Receptor Negative|HER2/Neu Negative|Metastatic Breast Cancer|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Triple Negative Breast Cancer||University of Washington|Merck Sharp & Dohme Corp.||April 1 2019||Phase 2|
|NCT03773302||Recruiting||Drug: BGJ398|Drug: Gemcitabine|Drug: Cisplatin||Advanced Cholangiocarcinoma|FGFR2 Gene Mutation||QED Therapeutics Inc.||April 2019||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
What is the appropriate concentration of DMF for cell culture and animal study?
It depends on the cell type. The final concentration of DMF should be better limited to less than 0.1% if possible, or below 1%. Using saline as a vehicle for cisplatin at up to 3mg/ml is recommended. it's a suspension and can be administrated via oral gavage.